Excellent.

BIOLASE to Explore Possible M&A Transactions

http://ih.advfn.com/p.php?pid=nmona&article=59972842&symbol=BIOL

Video on Nanofilm, Ltd.

http://www.nanofilmtechnology.com/news/index.aspx

APNT working with Solexel one of Kleiner Perkins investments in solar.

http://www.greentechmedia.com/articles/read/Solexel-SunPower-Backed-Thin-Silicon-Startup-Gets-14.8M-in-VC

New study boosts new prospects of world of possibilities for placental-derived cell therapy

By Dusty Garza, BioMedReports
Monday, 19 August 2013 22:27

http://www.biomedreports.com/20130820149621/new-study-boosts-new-prospects-of-world-of-possibilities-for-placental-derived-cell-therapy.html

...One key player in the placental cell therapy space, Pluristem Therapeutics (NASDAQ: PSTI) may be open to joining Osiris in the ring. The Israeli biotechnology firm is harvesting mesenchymal stem cells (MSCs) from human placentas that is the starting material for their PLacental eXpanded (PLX) cells products. PLX cell therapies can be administered as ready-to-use, “off the shelf” treatments that need no matching prior to administration.

Interestingly, the placental-derived MSCs used by Osiris in their Grafix product are the same MSCs used by Pluristem as their cell source to produce PLX cells. Presently, the company is in Phase I or II clinical trials in the areas of Peripheral Artery Disease (critical limb ischemia and intermittent claudication) and Muscle Injuries (adjuvant hip replacement and athletic injuries). Pluristem CEO Zami Aberman told Fast Company that the MSCs cells obtained from "one placenta can help treat 10,000 people."

Pluristem is at a clear advantage, first, because the Company is not relying on any contract manufacturer. Under the procedures and protocols that it has pioneered, it is able to modulate the performance of its PLX cells for specific indications by modifying and optimizing the conditions under which they are expanded. In other words, it can modify what the cells do.

Second, placental cells are easily obtainable, and they are particularly amenable to expansion. Collecting placentas is not inconvenient to donors. Pluristem also seems to be particularly adept at finding ways to fund the various indications it is exploring as potential indications. It is also studying exactly what the cells do to better understand how they function, which could help guide the company to new indications.

Given the great results from the recent Osiris study, the company may be open to jumping into the diabetic foot ulcer area since Pluristem has access to the abundant supply of viable, multi-potent MSCs, fibroblasts and epithelial cells would needed to make the wound-care matrix say officials of the company.

No doubt that small-cap companies such as Pluristem want to get into the ring with Osiris Therapeutics. There are profits to be made in the area--approximately $30 billion is spent annually in the therapeutic and regenerative cellular market.

Misleading Mike. SMME is a reporting company. http://www.otcmarkets.com/stock/SMME/company-info

Caveat Emptor is a commonly understood pink sheet status for a publicly traded OTC stock that is no longer in SEC reporting status.

You are free to complain all you want about how you bought at the top and never sold or averaged down and you think it is going to zero but you hold anyway. However, being misleading as to a companies SEC reporting status is just wrong. JMHO

Anyone here have Managements ear?

Would they consider buying the 1-800-dentist business and use their TV/radio marketing for consumers awareness that a pain-free, no sedation less invasive (less of your tooth is removed) and "no drill noise" option is available today? That would be brilliant because then they would be able to refer those who inquire to the nearest dentist that is using the Biolase technology and support the dentists that use their products. If you build a better mouse trap you have to make people aware it exist and then they must have it. JMHO

Hydrogen wars: car companies to form alliances to reduce fuel consumption
Thursday, July 18, 2013

http://www.northjersey.com/news/215941601_Hydrogen_wars__car_companies_to_form_alliances_to_reduce_fuel_consumption.html

Do you think that most press releases get issued for free?
Can you show me an example of a high quality reputable and free press release service? I can pay this company and get issued under PRNewswire. Do you like them better?

http://www.prnewswire.com/news-releases/is-there-really-any-difference-between-a-free-press-release-service-and-a-paid-24-7pressrelease-has-the-answer-189623061.html



Have they made press releases before claiming that they would be in production within a specific month and then failed to deliver? Do they have a history of PR'ing specific events and times that never happen? 10 years, was 10 years ago and today is today. All stocks have a point in time when they are a good time to buy and not a good time to buy. If you had bought AAPL at $700 would that make it a bad stock today at $400+ or just bad timing on a good company?



I said nothing about the lawsuit being in Sept. I did say that I have some hope that SMME will be able to launch their first product as they announced in Aug which is coming up fast.



Yes and I generally like to read what everyone has to say as long as there is some value and merit occasionally.



Actually, I am all for a balanced view with legitimate concerns that are current to the situation. I see nothing wrong with the PR company they use and it will not make or break their product or change the lawsuit with Visa Mastercard. I have concerns about market acceptance and cash flow for growth but these are part of the risk/reward for all microcaps.



Do you feel perfectly justified in putting a negative spin on all aspects of the company and have no concerns that you may have influenced someone from buying at under 10 cents who could be up over 300% right now? If SMME does do well with their medical key ring, will you have any regrets for possibly influencing someone to not buy the stock? Some people do speculate wildly and if you addressed them with reasonable expectations, I would value that.

Some answers can be found with a simple Google search.

http://techcrunch.com/2013/04/02/marketwire-is-now-marketwired-poaches-yahoos-big-data-vp-as-new-evp-of-product/

Marketwired also has PR's for some big board companies...

http://www.marketwire.com/press-release/mirati-therapeutics-to-commence-trading-on-the-nasdaq-tsx-myg-1810926.htm

The point is that the news service is widely distributed so that if you read Yahoo news you will get their PR's. Content is another subject and it is up to the company to publish PR's with good grammar and accurate information.

I would like to add that all start-up companies that have not released their first product are in development stage and anyone investing in them should already know the risk involved. If you did not agree to the risks involved in "penny stocks" then you should investigate suing your broker for allowing you to purchase SMME. Companies in a development stage remain in that stage until they offer a product for sale. Development often takes years and is costly and with microcap traded stocks shareholders usually bear the brunt in the from of dilution or bad financing. I don't know how many shares you bought but for your own well being you might want to think of each of them as a lottery ticket that did not expire in a week. You still have a chance and if they are able to produce and market a product next month then investor perception could change quickly. Having a product in hand could be good when going to court to ask for damages too. Nothing is for sure but ask yourself, "Do I want my shares to increase in price"? If the answer is "yes" then ask yourself, "If I had never heard of SMME before and I was intrigued by a commercial to check out the company before making a key ring purchase and Google brought me to ihub and I read Latenightmike57 's posts... (I think you get the idea). So how about we give this small company a little break until September and then if no product is released you can say "I told you so"? Remember you are not the only investor that is affected by the price of the stock.

The point at which a company goes from development to production is an important one and it looks possible that SMME could turn that corner very soon.

One last thing is that stocks that are pumped and dumped leaving disgruntled bagholders are not always connected with the company they promote. Sometimes the company is just as innocent as the bagholders that are created. If the company did not sell discounted shares to a stock promoter then can it really be blamed? If insiders did not sell into a promotional pump can they be blamed? If you really want to warn others would it not be more beneficial to follow the stock promoters and warn others about their promotion tactics? This is a real company with a real patent and a real lawsuit, real inside ownership and the hope of a real product, really soon. I hope the best for you and your SMME stock.

NanoViricides Reports That its CEO was Interviewed on the RedChip Money Report Program on Fox Bus. News TV Channel Yesterday

http://ih.advfn.com/p.php?pid=nmona&article=58485563

Harris & Harris Group Notes the Closing of the Sale of Xradia to Carl Zeiss

http://ih.advfn.com/p.php?pid=nmona&article=58466086

This sounds like great news but needs some numbers to calculate the benefit to shareholders.

Mesoblast Receives $4.3 Million from Australian Government for Adult Stem Cell Pipeline Development

http://ih.advfn.com/p.php?pid=nmona&article=58454681

DexCom Inc. Reports First Quarter 2013 Financial

http://ih.advfn.com/p.php?pid=nmona&article=57399906

I should not have hit the "ask"? Now you tell me - lol

If AAPL wants to keep out the copy cats then they need to buy-out LQMT. If not then everyone else will have to come to our door if they want to compete against Apple. Either way shareholders win. IMHO

Scientists create human liver from stem cells

By Kate Kelland

LONDON (Reuters) - Scientists have for the first time created a functional human liver from stem cells derived from skin and blood and say their success points to a future where much-needed livers and other transplant organs could be made in a laboratory.

While it may take another 10 years before lab-grown livers could be used to treat patients, the Japanese scientists say they now have important proof of concept that paves the way for more ambitious organ-growing experiments.

"The promise of an off-the-shelf liver seems much closer than one could hope even a year ago," said Dusko Illic, a stem cell expert at King's College London who was not directly involved in the research but praised its success.

He said however that while the technique looks "very promising" and represents a huge step forward, "there is much unknown and it will take years before it could be applied in regenerative medicine."

Researchers around the world have been studying stem cells from various sources for more than a decade, hoping to capitalize on their ability to transform into a wide variety of other kinds of cell to treat a range of health conditions.

There are two main forms of stem cells - embryonic stem cells, which are harvested from embryos, and reprogrammed "induced pluripotent stem cells" (iPS cells), often taken from skin or blood.

Countries across the world have a critical shortage of donor organs for treating patients with liver, kidney, heart and other organ failure. Scientists are keenly aware of the need to find other ways of obtaining organs for transplant.

The Japanese team, based at the Yokohama City University Graduate School of Medicine in Japan, used iPS cells to make three different cell types that would normally combine in the natural formation of a human liver in a developing embryo - hepatic endoderm cells, mesenchymal stem cells and endothelial cells - and mixed them together to see if they would grow.

They found the cells did grow and began to form three-dimensional structures called "liver buds" - a collection of liver cells with the potential to develop into a full organ.

When they transplanted them into mice, the researchers found the human liver buds matured, the human blood vessels connected to the mouse host's blood vessels and they began to perform many of the functions of mature human liver cells.

"To our knowledge, this is the first report demonstrating the generation of a functional human organ from pluripotent stem cells," the researchers wrote in the journal Nature.

Malcolm Allison, a stem cell expert at Queen Mary University of London, who was not involved in the research, said the study's results offered "the distinct possibility of being able to create mini livers from the skin cells of a patient dying of liver failure" and transplant them to boost the failing organ.

Takanori Takebe, who led the study, told a teleconference he was so encouraged by the success of this work that he plans similar research on other organs such as the pancreas and lungs.

A team of American researchers said in April they had created a rat kidney in a lab that was able to function like a natural one, but their method used a "scaffold" structure from a kidney to build a new organ.

And in May last year, British researchers said they had turned skin cells into beating heart tissue that might one day be able to be used to treat heart failure.

That livers and other organs may one day be made from iPS cells is an "exciting" prospect, said Matthew Smalley of Cardiff University's European Cancer Stem Cell Research Institute.

"(This) study holds out real promise for a viable alternative approach to human organ transplants," he said.

Chris Mason, a regenerative medicine expert at University College London said the greatest impact of iPS cell-liver buds might be in their use in improving drug development.

"Presently to study the metabolism and toxicology of potential new drugs, human cadaveric liver cells are used, " he said. "Unfortunately these are only available in very limited quantities".

The suggestion from this new study is that mice transplanted with human iPS cell-liver buds might be used to test new drugs to see how the human liver would cope with them and whether they might have side-effects such as liver toxicity.

(This story refiles to fix a typo in the name "Yokohama" in the eighth paragraph)

(Reporting by Kate Kelland; Editing by Janet Lawrence)

http://news.yahoo.com/scientists-create-human-liver-stem-cells-033554646.html

Can We Realize the Promise of Cell Therapy?

Eytan Abraham, Product Innovation Research Manager, Pluristem Therapeutics
Thursday, June 27, 2013 16:45 EDT


Cell therapy is poised to spark a paradigm shift in medicine. Harnessing the power of the cell, the basic living unit of our body, will allow for limitless possibilities -- from producing artificial organs, to promoting self-healing by injecting cells in suspension, and everything in between.
The promise of cell therapy is beginning to be acknowledged by both big pharma and generics alike: Genzyme, Teva, Shire, and others are all significantly invested in the cell therapy space. As of 2012, there were more than 100 ongoing cell therapy trials in the US alone, aimed at treating a variety of indications, from neurodegenerative to orthopedic.

But what will it take to transform cell therapy into an industry, producing therapies for hundreds of thousands of patients?

Safety, efficacy, and understanding the mechanisms of action, are all obvious answers.

But have you ever considered how many cells it takes to make a heart? There are about 2 billion muscle cells in an adult heart, and many cell therapy treatments require hundreds of millions of cells per dose. Treating 10,000 patients with a dose of 300 million cells each would require 3 trillion cells!

Try to produce these amounts of cells using traditional plastic flasks.

So, how can these vast amounts of cells be produced? Moreover, how can cell therapy companies produce this complex product, using a robust and stable process, at an acceptable price point?

These questions present significant challenges, especially given that cell therapy consists of a live product that responds to external stimuli ("the process is the product") and requires complex and costly manufacturing processes.

Producing these cells in three-dimensional environments in bioreactors offers a solution, and one that is already available.

Why 3D and why bioreactors? Adherent cells need a surface to grow on, the more surface you have, the more cells you can produce. 3D culture of cells, whether in scaffolds or in cell aggregates, allows for a multifold increase in the efficiency of cell culture. The more surface area, the more cells can be cultured in a given volume.

At present, very few cell therapy companies are pursuing the 3D cell culture strategy. Taking Pluristem Therapeutics as an example, one 5-liter packed bed bioreactor with 3D scaffold (FibraCel) yields a number of cells equivalent to approximately 70 2D 10-layer "cell factory" flasks. This represents a 3D advantage in efficiency of cells produced per volume of more than 70-fold.

Another example is ReGenesys (an affiliate of Athersys), which is experimenting with the use of the hollow fiber-based Quantum Cell Expansion System from CaridianBCT for large-scale cell culture.

Such efficiencies, resulting from 3D cell culture, represent the approach to reach the cell numbers needed to turn cell therapy into a relevant industry. Moreover, such 3D culture approaches can also cut production costs very significantly.

As for bioreactors, the key phrase to remember here is "the product is the process." Control over the cell culture process is critical. Cells will respond during culture to any change in conditions. Changes in pH, glucose levels, oxygen, etc., will result in changes to the cell biology and therefore the final product.

Culture in bioreactors allows precise online control over all these parameters, as opposed to 2D flask-based culture in which parameters are not monitored or controlled online.

The bottom line is that the 2D flask approach to cell culture will be difficult to scale up to the degree needed if cell therapy is to become a global industry. Solutions, in the form of 3D culture in bioreactors, are available, but must be acknowledged, embraced, and further developed if cell therapy is to become a reality.

http://www.pharmaevolution.com/author.asp?section_id=3105&doc_id=560363

IBIO chart

Pluristem CEO, Zami Aberman Answers the Tough Questions

http://finance.yahoo.com/news/pluristem-ceo-zami-aberman-answers-142323159.html

Wow that was ugly:( Nice volume though;) End of day got better. Maybe the large short position covered and all the new eyeballs will look deeper into the IP PSTI owns and all the other studies they have going on.

PSTI chart

Pluristem to Present at FDA Symposium
http://ih.advfn.com/p.php?pid=nmona&article=57757776

Looks like something positive happened?

Clovis Oncology’s CO-1686 Demonstrates Encouraging Results from Ongoing Phase I/II Study in EGFR-mutant Non-Small Cell Lung

http://ih.advfn.com/p.php?pid=nmona&article=57820843&symbol=CLVS

PSTI Pluristem has been getting a lot of good news lately. They had a secondary last year @ $4.00 that put them into a good cash position. They have a state-of-the-art patented 3D bio-reactor manufacturing plant and method of transport for their Stem cells which come from placenta. They have a deal with UTHR and many other irons in the fire. Also has a high short ratio, FWIW

Next gen hydrogen fuel cells and inexpensive production of hydrogen is getting serious attention and no matter which company gets to market first, they will all want APNT 's patented lightweight nano carbon fiber fuel tanks, JMHO.

Of course, Samsung could use the APNT tech that they licensed on their 4k televisions and then everyone else will have to line up and pay up or be left out of the market, BWDIK. Could be really interesting if Apple decided to make their new apple tv without samsang and licensed APNT SED TV tech. Speculation is endless.

Too many really good possibilities here to try and guess which one will take off first. Could it be the nano-fiber light weight body armor for the military? Or could it be the citrus testing equipment that California is partially funding?
Solar inks? Computer chip cooling tech? Golf clubs? The IP is incredible next generation stuff and hopefully they can get a "connected CEO" and make it happen.

King’s College Hospital launches first brain cancer vaccine

http://www.kch.nhs.uk/news/media/press-releases/view/12102

SMME vs MC Visa 13 Billion?

NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer

http://ih.advfn.com/p.php?pid=nmona&article=57702175&symbol=NWBO

Thanks - http://www.aethlonmedical.com/products/aethlon-adapt.htm

They have the right focus for investors, IMHO...
IDE > Darpa Sepsis >

On the hemopurifier device, after it "filters" the blood with the designated media, does the current design allow for adding something new to mix into the bloodstream (I'm thinking of ozone but I'm sure there are other applications)?

http://finance.yahoo.com/news/pluristem-welcomes-parliamentary-state-secretary-093000718.html

Todays price could just be the beginning for ZNNMF. The deal with eeStor could be huge if the May 30th tests breaks current benchmarks for ultra-capacitors.

ZNNMF aka ZNN.V chart

I gave you a PM week ago Friday.

Did you get any ZNNMF?

NWBO chart

You should have bought more!!! Need to do the back to the future thing. lol

BIOL chart

ZNNMF ZNN.V chart

PSTI chart

May 30th Test results - Stay tuned for the eeStor explosion (I doubt they would set up a test for an implosion but I have been wrong before.